Caribou Biosciences to Participate in Upcoming Investor Conferences
Caribou Biosciences to Participate in Upcoming Investor Conferences
BERKELEY, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou's president and chief executive officer, will participate in the following investor conferences:
加利福尼亞州伯克利，2024年11月20日（全球新聞網）——加勒比生物科學公司（納斯達克：CRBU），一家領先的臨床階段CRISPR基因編輯生物製藥公司，今天宣佈公司總裁兼首席執行官瑞秋·哈爾維茨博士將參加以下投資者會議：
-
Citi's 2024 Global Healthcare Conference, Miami, FL
December 3, 2024, panel at 2:30 PM EST
Panel title: Cell therapies in autoimmune disorders
Webcast
- 花旗銀行2024年全球醫療健康會議，邁阿密，佛羅里達州
2024年12月3日，面板討論在東部標準時間下午2:30
討論主題：自身免疫性疾病中的電芯治療
網絡直播
-
7th Annual Evercore ISI HealthCONx Conference, Coral Gables, FL
December 4, 2024, fireside chat at 10:25 AM EST
Webcast
- 第七屆evercore ISI HealthCONx會議，科拉爾蓋布爾斯，佛羅里達州
2024年12月4日，爐邊聊天在東部標準時間上午10:25
網絡直播
For more information, visit the Events page on Caribou's website. Webcasts will be available on the Caribou website for 30 days after the event.
欲了解更多信息，請訪問Caribou網站上的活動頁面。活動結束後，網絡直播將在Caribou網站上提供30天。
About Caribou's novel next-generation CRISPR platform
CRISPR genome editing uses easily designed, modular biological tools to make DNA changes in living cells. There are two basic components of Class 2 CRISPR systems: the nuclease protein that cuts DNA and the RNA molecule(s) that guide the nuclease to generate a site-specific, double-stranded break, leading to an edit at the targeted genomic site. CRISPR systems are capable of editing unintended genomic sites, known as off-target editing, which may lead to harmful effects on cellular function and phenotype. In response to this challenge, Caribou has developed CRISPR hybrid RNA-DNA guides (chRDNAs; pronounced "chardonnays") that direct substantially more precise genome editing compared to all-RNA guides. Caribou is deploying the power of its chRDNA technology to carry out high efficiency multiple edits, to develop CRISPR-edited therapies.
關於Caribou的新一代CRISPR平台
CRISPR基因組編輯使用易於設計的、模塊化的生物工具在活體細胞中進行DNA改變。Class 2 CRISPR系統有兩個基本元素：切割DNA的核酸酶蛋白和RNA分子，它們指導核酸酶在特定的基因組位點上產生特異性的雙鏈斷裂，從而在目標基因組位點上發生編輯。CRISPR系統能夠編輯稱爲「非靶向編輯」的意外基因組位點，這可能對細胞功能和表型產生有害影響。針對這一挑戰，Caribou開發了CRISPR雜交RNA-DNA指南（chRDNA；發音爲「夏多內」），相對於全RNA指南，它們可以更精確地定向基因組編輯。Caribou正在利用其chRDNA技術的威力進行高效率的多個編輯，並開發CRISPR編輯的治療方案。
About Caribou Biosciences, Inc.
Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company's genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T platform as readily available treatments for patients with hematologic malignancies and autoimmune diseases. Follow us @CaribouBio and visit .
關於Caribou Biosciences, Inc。
Caribou Biosciences是一家臨床階段的CRISPR基因編輯生物醫藥公司，致力於爲患有毀滅性疾病的患者開發變革性療法。該公司的基因組編輯平台，包括其Cas12a chRDNA技術，具有超強的精度，可以開發針對疾病的細胞療法。Caribou正在推進基於其CAR-t平台的一系列可用的供體細胞療法，作爲血液系統惡性腫瘤和自身免疫性疾病患者可用的治療方法。關注我們@CaribouBio並訪問。
Caribou Biosciences, Inc. contacts:
Investors:
Amy Figueroa, CFA
investor.relations@cariboubio.com
Caribou Biosciences，Inc.聯繫方式：
投資者:
Amy Figueroa，CFA
investor.relations@cariboubio.com
Media:
Peggy Vorwald, PhD
media@cariboubio.com
媒體:
Peggy Vorwald，PhD
media@cariboubio.com
譯文內容由第三人軟體翻譯。